Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Sandeep, D. S.
- Formulation and Evaluation Ungual Drug Delivery System of Antifungal Agent for Nail Disorders
Abstract Views :155 |
PDF Views:1
Authors
R. Narayana Charyulu
1,
D. S. Sandeep
1,
Abhishiktha Alva
1,
Divya Rao
1,
Prashant Nayak
1,
Jobin Jose
1,
K. C. Bahrath Raj
2
Affiliations
1 Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Nitte University, Paneer, Deralakatte, Mangalore, Karnataka, IN
2 Department of Pharmacology, NGSM Institute of Pharmaceutical Sciences, Nitte University, Paneer, Deralakatte, Mangalore, Karnataka, IN
1 Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Nitte University, Paneer, Deralakatte, Mangalore, Karnataka, IN
2 Department of Pharmacology, NGSM Institute of Pharmaceutical Sciences, Nitte University, Paneer, Deralakatte, Mangalore, Karnataka, IN
Source
Research Journal of Pharmacy and Technology, Vol 10, No 3 (2017), Pagination: 869-872Abstract
Fungal infections affecting nails are commonly seen around the world. The effectiveness of topical therapies is limited by minimal drug permeability through the nail plate. Nail permeability is however quite low and limits topical therapy to early/mild disease states such as onychomycosis (fungal infections of the nail). The current research aims at ungual drug delivery system as an effective treatment in nail infections. The formulations of nail lacquer were made with Amorolfine as antifungal agent using different concentration of polymer Eudragit RL 100 (ERL 100). Among 6 formulations, formulation F5 and F6 showed very good physical characteristics like viscosity, water resistance, stability, drying time, smoothness as compared to other formulations. The zone of inhibition of antifungal activity showed desired results (F5 and F6).Keywords
Nail Lacquer, Polymer, Ungual Drug Delivary, Viscosity.
- Design and Evaluation of Bigels Containing Flurbiprofen
Abstract Views :222 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University) Paneer, Deralakatte, Mangalore, Karnataka, IN
1 Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University) Paneer, Deralakatte, Mangalore, Karnataka, IN
Source
Research Journal of Pharmacy and Technology, Vol 11, No 1 (2018), Pagination: 143-152Abstract
The present study was aimed of design and evaluation of bigel containing flurbiprofen. Bigels are interesting innovative two phase systems that have been recently proposed as structured system for delivery of active ingredients. They possess the advantages of both hydrogel and organogel. Organogel was prepared by pluronic lecithin and hydrogel was prepared using HPMC. Bigels were prepared by mixing of organogel and hydrogel in appropriate ratio. Organogel and hydrogel was evaluated for pH, viscosity, extrudability and spreadabilty. Formulation F3 from organogel and formulation H3 from hydrogel was selected as optimized formulations and was used for the preparation of bigel. The prepared bigel was evaluated for pH, viscosity, extrudability, spread ability, in vitro drug release studies, ex vivo permeation studies, stability studies and skin irritation test. All formulations of bigel showed extended release out of which formulation B3 was selected as the optimized formulation on the basis of evaluation parameters. In vitro permeation release was found to be 89.99% at the end of 8 hrs. The release kinetics of flurbiprofen bigel followed Higuchi model. The bigels were found to be stable and skin irritation studies on Wistar rats showed that the prepared bigels were compatible. Based on the encouraging results bigels containing flurbiprofen can be used as extended release system.Keywords
Flurbiprofen, Organogel, Hydrogel, Bigel, HPMC.References
- Tortora GJ, Derrickson B. Anatomy and physiology.1st ed. India edition, 2015, Wiley Publishers, pp. 125-137.
- Enas Ahmed. Hydrogel: Preparation, characterization and applications: A review. J Adv Res. 6(1); 2015: 105–121.
- Mahmoud Mokhtar I, Salma Hafez A, Mahmoud Mahdy M. Organogels, hydrogels and bigels as transdermal delivery systems for diltiazem hydrochloride. Asian J Pharma Sci. 8; 2013:48-57.
- Lupi FR, Ahmed S, Greco V, Rossi CO, Baldino N. A rheological and micro structural characterization of bigels for cosmetic and pharmaceutical uses. Material Sci and Eng. 69; 2016:358-365.
- Lupi FR, Gentle L, Baldino N. Olive oil and hyper thermal water bigels for cosmetic use. J Colloid and Interface Sci. 4(5); 2015:70-78.
- Akhtar MF, Hafez SA, Mahdy MM. Organogels, hydrogels and bigels as transdermal delivery of diltiazem hydrochloride. Asian J Pharm Sci. 8; 2013:48-57.
- Banks SR, Bajwa GS, Timmins P. The influence of substituted phenols on the sol: gel transition of hydroxypropyl methylcellulose (HPMC) aqueous solutions. Carbohydrate Polymers.101; 2014:1198-1204.
- Makwana SB, Patel VA, Parmer SJ. Development and characterization of in situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride. Res Pharm Sci. 6(1); 2016:1-6.
- Chandira RM and Pradeep PA. Design, development and formulation of Antiacne Dermatological Gel. J Chem Pharm Res. 2(1); 2010:401-404.
- Vikrant J, Sonali N. Formulation and evaluation of topical flurbiprofen gel using different gellying agents. World J Pharma Sci. 3(9); 2013:654-663.
- Khan AW, Kotta S, Ansari SH, Sharma RK, Kumar A. Formulation, development, optimization and evaluation of aloe vera gel for wound healing. Pharmacogn Mag. 9(1); 2013: 6-10.
- Singh VK, Anis A, Banarjee I. Preparation and characterization of novel carbopol based bigels for topical delivery of metronidazole for the treatment of bacterial vaginosis. Materials Sci and Eng. 44; 2014:151-158.
- Shaikh IM. et al. Aceclofenac Organogels: In vitro and in vivo Characterization. Curr Drug Deliv. 6(1);2009: 1-7.
- Sakarkar DM, Shrikande VN, Vyas JV, Mahajan N. Studies on formulation development, characterization and transdermal permeation of nimesulide from emulgel. Int J Pharm Excip. 16(5); 2004: 381-387.
- Guleri KT, Preet KL. Formulation and evaluation of topical gel of aceclofenac. J Drug Deliv Therapeutics. 3(6); 2013: 51-53.
- Tazrart A, Bolzinger MA, Moureau A, Molina T, Coudert S. Penetration and decontamination of americium-241 ex vivo using fresh and frozen pig skin. Chem Bio Inter. 267; 2017:40-47.
- Nava G, Pinon E, Mendosa L, Mendosa N. Formulation and in vitro, ex vivo and in vivo evaluation of elastic liposomes for transdermal delivery of ketorolac tromethamine. Int J Pharm. 3; 2011:954-970.
- Jain S, Goswami M, Bhandari A. Skin irritation study in transdermal patch of chitosan containing trazodane HCl on rat skin. Int J Res Pharm Bio Sci.2011;2(3)1082-1084.
- WHO-GMP and ICH stability testing guidelines for drug products. The pharm Sci Pharm Pathway.2.72-2.79.
- Regulatory Approval Process for Drugs in Canada-A Challenging Task
Abstract Views :375 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutical Regulatory Affairs, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Paneer, Deralakatte, Mangaluru-575018, Karnataka, IN
1 Department of Pharmaceutical Regulatory Affairs, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Paneer, Deralakatte, Mangaluru-575018, Karnataka, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 7 (2019), Pagination: 3206-3210Abstract
The drugs and medical devices for human use in Canada are regulated by Health Canada’s Therapeutic Products Directorate (TPD). Health Canada is responsible to implement the rules and regulations for the marketing of drugs. Health Canada’s process for approving new drugs is very slow and they give approval for drug products based on a complete review of safety and efficacy data. In Canada, around 70% of the new drugs were submitted over three months, and 40% more than one year, after their first submission. For drugs that were eventually approved to be marketed in Canada and in at least one of the other jurisdictions, the average delay from the first submission in either foreign jurisdiction to submission in Canada was 540 days. A drug approval process is completed by various applications submitted to the authority and the registration of drugs in Canada is really challenging. The purpose of this article is to provide information about the procedure from pre-submission to the marketing of a pharmaceutical drug for obtaining the drug approval in Canada.Keywords
Health Canada, ANDS, CTA, HPFB, NDS.References
- Ali Shajarizadeh MA, Aiden Hollis. Delays in the submission of new drugs in Canada. CMAJ. 187(1), Jan 2015:47-51.
- Canada H, Products H, Branch F, Products Directorate T. mands_gespd-eng.pdf.[cited 2018 May 02]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhpmps/alt_formats/pdf/prodpharma/applic-demande/guide-ld/mgmt-gest/mands_gespd-eng.pdf.
- Distribution and marketing of drugs in Canada: Overview. [cited 26 April 2018]. Available from:https://content.next.westlaw.com/Document/Iffa811f25ac111e598dc8b09b4f043e0/View/FullText.html?contextData=(sc.Default) & transition Type=Default & first Page = true & bhcp=1
- DSM Sinochem Pharmaceuticals. Drug products. [cited 27 April 2018]. Available from: http://www.dsm-sinochem.com/About-Us/Our-global-network/Drug-Products.
- Government of Canada HC. Description: Appendix 6c: Abbreviated New Drug Submission (ANDS) or Supplement to an Abbreviated New Drug Submission (SANDS). [cited 2018 May 01]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/compli-conform/noccg_accd-longdesc3-eng.php
- How drugs are reviewed in Canada. [cited 27 April 2018]. Available from:https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/fact-sheets/drugs-reviewed-canada.html.
- Lexchin J. Health Canada’s use of its priority review process for new drugs: A cohort study. BMJ Open 2015;5: e006816. doi:10.1136/bmjopen-2014- 006816. Available from: http://dx.doi.org/10.1136/
- Mulaje SS. Procedure for drug approval in different countries: A Review. J Drug Deliv Ther. 3(2); 2013:1–21.
- Preeti MS et.al. New drug approval procedure in different countries: A Review. Int J Chem Tech Res. 10(12), 2017:1-21.
- Regulating Pharmaceutical Drugs- Health Canada. [cited 2018 April 27]. Available from: http://www.oagbvg.gc.ca/internet/English/parl_oag_201111_04_e_35936.html.
- Richard YC, Goodwin SH. An overview of Canadian and U.S. Approaches to drug regulation and responses to post market adverse drug reactions. J Diabetes Sci Technol. 7(2); 2013: 313-320.
- Shakeel SM et.al. Comparison of regulatory requirements for generic drugs dossier submission in United states and Canada. Int J Pharm Sci and Health care. 6(6); 2016: 1-19.